Legend Biotech (LEGN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

LEGN Stock Forecast

Legend Biotech stock forecast is as follows: an average price target of $82.69 (represents a 116.52% upside from LEGN’s last price of $38.19) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.

LEGN Price Target

The average price target for Legend Biotech (LEGN) is $82.69 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $94.00 to $60.00. This represents a potential 116.52% upside from LEGN's last price of $38.19.

LEGN Analyst Ratings

Buy

According to 14 Wall Street analysts, Legend Biotech's rating consensus is 'Buy'. The analyst rating breakdown for LEGN stock is 0 'Strong Buy' (0.00%), 13 'Buy' (92.86%), 1 'Hold' (7.14%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Legend Biotech Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 13, 2024	Rick Bienkowski	Cantor Fitzgerald	$83.00	$55.90	48.48%	117.33%
Oct 15, 2024	Justin Zelin	BTIG	$91.00	$44.91	102.63%	138.28%
Oct 15, 2024	Gena Wang	Johnson Rice	$94.00	$45.24	107.76%	146.14%
Oct 15, 2024	Gena Wang	Barclays	$94.00	$44.91	109.31%	146.14%
Oct 08, 2024	Qize Ding	Redburn Partners	$86.00	$49.58	73.46%	125.19%
Jun 17, 2024	Edward Tenthoff	Piper Sandler	$90.00	$42.00	114.29%	135.66%
Jun 17, 2024	Asthika Goonewardene	Truist Financial	$88.00	$42.45	107.30%	130.43%
May 23, 2024	James Shin	Deutsche Bank	$60.00	$40.04	49.85%	57.11%
May 17, 2024	Matthew Harrison	Morgan Stanley	$82.00	$46.37	76.84%	114.72%
May 14, 2024	Leonid Timashev	RBC Capital	$86.00	$42.97	100.14%	125.19%

Row per page

Go to

The latest Legend Biotech stock forecast, released on Nov 13, 2024 by Rick Bienkowski from Cantor Fitzgerald, set a price target of $83.00, which represents a 48.48% increase from the stock price at the time of the forecast ($55.90), and a 117.33% increase from LEGN last price ($38.19).

Legend Biotech Price Target by Period

	1M	3M	12M
# Anlaysts	1	5	13
Avg Price Target	$83.00	$89.60	$83.92
Last Closing Price	$38.19	$38.19	$38.19
Upside/Downside	117.33%	134.62%	119.74%

In the current month, the average price target of Legend Biotech stock is $83.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 117.33% increase as opposed to Legend Biotech's last price of $38.19. This month's average price target is down -7.37% compared to last quarter, and down -1.10% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 13, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
Oct 16, 2024	BMO Capital	Outperform	Outperform	Hold
Oct 16, 2024	Johnson Rice	Buy	Buy	Hold
Oct 15, 2024	BTIG	Buy	Buy	Hold
Oct 15, 2024	Johnson Rice	Overweight	Overweight	Hold
Oct 15, 2024	Barclays	Overweight	Overweight	Hold
Oct 11, 2024	Cowen & Co.	Buy	Buy	Hold
Oct 04, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 27, 2024	RBC Capital	Underperform	Underperform	Hold
Sep 27, 2024	Scotiabank	Buy	Buy	Hold

Row per page

Go to

Legend Biotech's last stock rating was published by Cantor Fitzgerald on Nov 13, 2024. The company gave LEGN a "Overweight" rating, the same as its previous rate.

Legend Biotech Financial Forecast

Legend Biotech Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$36.34M	$25.21M	-	$11.97M	$40.83M	$38.99M	$16.88M	$20.23M	$13.68M	$40.78M	$11.75M	$11.60M
Avg Forecast	$474.50M	$432.20M	$393.67M	$358.58M	$305.33M	$263.87M	$253.43M	$197.15M	$178.98M	$143.91M	$125.25M	$143.24M	$94.08M	$97.25M	$56.64M	$42.18M	$32.34M	$32.34M	$33.62M	$25.00M	$14.27M	$7.83M	$9.13M	$6.50M	$13.00M	$13.00M	$13.00M
High Forecast	$538.03M	$490.07M	$446.38M	$406.59M	$346.22M	$299.20M	$287.36M	$212.73M	$197.69M	$147.90M	$125.25M	$143.24M	$106.19M	$110.28M	$64.22M	$47.82M	$36.67M	$32.34M	$33.62M	$25.00M	$14.27M	$7.83M	$9.13M	$6.50M	$13.00M	$13.00M	$13.00M
Low Forecast	$428.34M	$390.15M	$355.37M	$323.69M	$275.63M	$238.20M	$228.77M	$184.06M	$158.28M	$139.93M	$125.25M	$143.24M	$81.55M	$87.79M	$51.13M	$38.07M	$29.20M	$32.34M	$33.62M	$25.00M	$14.27M	$7.83M	$9.13M	$6.50M	$13.00M	$13.00M	$13.00M
# Analysts	2	2	2	2	1	1	1	4	9	4	3	4	7	5	6	3	2	2	2	2	3	4	5	6	6	3	3
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.86%	0.78%	-	0.36%	1.63%	2.73%	2.16%	2.22%	2.10%	3.14%	0.90%	0.89%

Legend Biotech's average Quarter revenue forecast for Jun 23 based on 6 analysts is $56.64M, with a low forecast of $51.13M, and a high forecast of $64.22M. LEGN's average Quarter revenue forecast represents a 55.87% increase compared to the company's last Quarter revenue of $36.34M (Mar 23).

Legend Biotech EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	2	2	2	2	1	1	1	4	9	4	3	4	7	5	6	3	2	2	2	2	3	4	5	6	6	3	3
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-126.86M	$317.86M	-	$-125.53M	$-71.07M	$-87.73M	$-124.54M	$-91.53M	$-80.86M	$-61.73M	$-66.96M	$-134.79M
Avg Forecast	$-474.50M	$-432.20M	$-393.67M	$-358.58M	$-305.33M	$-263.87M	$-253.43M	$-197.15M	$-178.98M	$-143.91M	$-125.25M	$-143.24M	$-94.08M	$-97.25M	$-56.64M	$-42.18M	$-32.34M	$-32.34M	$-33.62M	$-25.00M	$-14.27M	$-7.83M	$-9.13M	$-92.41M	$-13.00M	$-13.00M	$-345.26M
High Forecast	$-428.34M	$-390.15M	$-355.37M	$-323.69M	$-275.63M	$-238.20M	$-228.77M	$-184.06M	$-158.28M	$-139.93M	$-125.25M	$-143.24M	$-81.55M	$-87.79M	$-51.13M	$-38.07M	$-29.20M	$-32.34M	$-33.62M	$-25.00M	$-14.27M	$-7.83M	$-9.13M	$-73.93M	$-13.00M	$-13.00M	$-276.21M
Low Forecast	$-538.03M	$-490.07M	$-446.38M	$-406.59M	$-346.22M	$-299.20M	$-287.36M	$-212.73M	$-197.69M	$-147.90M	$-125.25M	$-143.24M	$-106.19M	$-110.28M	$-64.22M	$-47.82M	$-36.67M	$-32.34M	$-33.62M	$-25.00M	$-14.27M	$-7.83M	$-9.13M	$-110.90M	$-13.00M	$-13.00M	$-414.32M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.01%	-9.83%	-	3.73%	2.84%	6.15%	15.90%	10.02%	0.88%	4.75%	5.15%	0.39%

3 analysts predict LEGN's average Quarter EBITDA for Mar 23 to be $-42.18M, with a high of $-38.07M and a low of $-47.82M. This is -113.27% lower than Legend Biotech's previous annual EBITDA (Dec 22) of $317.86M.

Legend Biotech Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	2	2	2	2	1	1	1	4	9	4	3	4	7	5	6	3	2	2	2	2	3	4	5	6	6	3	3
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-112.10M	$319.93M	-	$-193.23M	$-42.08M	$-84.62M	$-121.25M	$-91.58M	$-82.21M	$-57.83M	$-66.55M	$-213.63M
Avg Forecast	$77.83M	$63.40M	$43.70M	$26.79M	$-6.34M	$-18.60M	$-23.01M	$-34.42M	$-44.67M	$-60.21M	$-52.49M	$-35.33M	$-64.93M	$-56.63M	$-65.91M	$-76.23M	$-68.17M	$-68.17M	$-56.64M	$-65.43M	$-62.41M	$-75.89M	$-61.17M	$-92.46M	$-51.74M	$-56.00M	$-345.49M
High Forecast	$91.37M	$74.44M	$51.30M	$31.45M	$-5.54M	$-16.24M	$-20.10M	$-20.43M	$-18.73M	$-52.60M	$-45.85M	$-30.86M	$-38.96M	$-49.47M	$-57.57M	$-66.59M	$-59.55M	$-68.17M	$-56.64M	$-65.43M	$-62.41M	$-75.89M	$-61.17M	$-73.96M	$-51.74M	$-56.00M	$-276.39M
Low Forecast	$67.98M	$55.38M	$38.17M	$23.40M	$-7.45M	$-21.83M	$-27.01M	$-41.94M	$-86.47M	$-70.69M	$-61.62M	$-41.48M	$-79.77M	$-66.48M	$-77.38M	$-89.50M	$-80.04M	$-68.17M	$-56.64M	$-65.43M	$-62.41M	$-75.89M	$-61.17M	$-110.95M	$-51.74M	$-56.00M	$-414.59M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.47%	-4.69%	-	3.41%	0.64%	1.36%	1.60%	1.50%	0.89%	1.12%	1.19%	0.62%

Legend Biotech's average Quarter net income forecast for Mar 23 is $-76.23M, with a range of $-89.50M to $-66.59M. LEGN's average Quarter net income forecast represents a -123.83% decrease compared to the company's last Quarter net income of $319.93M (Dec 22).

Legend Biotech SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	2	2	2	2	1	1	1	4	9	4	3	4	7	5	6	3	2	2	2	2	3	4	5	6	6	3	3
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$40.16M	$-242.82M	-	$45.49M	$33.96M	$69.95M	$31.34M	$26.03M	$22.16M	$33.35M	$15.32M	$14.06M
Avg Forecast	$510.86M	$465.32M	$423.84M	$386.06M	$328.73M	$284.09M	$272.85M	$212.25M	$192.69M	$154.94M	$134.85M	$154.22M	$101.29M	$104.71M	$60.98M	$45.41M	$34.82M	$34.36M	$35.71M	$26.56M	$15.16M	$8.32M	$9.70M	$6.90M	$13.81M	$13.81M	$13.81M
High Forecast	$579.26M	$527.62M	$480.59M	$437.75M	$372.75M	$322.13M	$309.38M	$229.03M	$212.84M	$159.23M	$134.85M	$154.22M	$114.33M	$118.73M	$69.14M	$51.49M	$39.48M	$34.36M	$35.71M	$26.56M	$15.16M	$8.32M	$9.70M	$6.90M	$13.81M	$13.81M	$13.81M
Low Forecast	$461.16M	$420.05M	$382.61M	$348.50M	$296.75M	$256.45M	$246.30M	$198.16M	$170.40M	$150.65M	$134.85M	$154.22M	$87.80M	$94.52M	$55.04M	$40.99M	$31.43M	$34.36M	$35.71M	$26.56M	$15.16M	$8.32M	$9.70M	$6.90M	$13.81M	$13.81M	$13.81M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.88%	-6.97%	-	1.27%	1.28%	4.61%	3.77%	2.68%	3.21%	2.42%	1.11%	1.02%

Legend Biotech's average Quarter SG&A projection for Jun 23 is $60.98M, based on 6 Wall Street analysts, with a range of $55.04M to $69.14M. The forecast indicates a 51.84% rise compared to LEGN last annual SG&A of $40.16M (Mar 23).

Legend Biotech EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	2	2	2	2	1	1	1	4	9	4	3	4	7	5	6	3	2	2	2	2	3	4	5	6	6	3	3
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.68	$2.01	-	$-1.25	$-0.27	$-0.58	$-0.84	$-0.66	$-0.62	$-0.44	$-0.50	$-1.98
Avg Forecast	$0.43	$0.35	$0.24	$0.15	$-0.03	$-0.10	$-0.13	$-0.19	$-0.24	$-0.33	$-0.29	$-0.19	$-0.36	$-0.31	$-0.36	$-0.42	$-0.37	$-0.37	$-0.31	$-0.36	$-0.34	$-0.42	$-0.34	$-0.35	$-0.28	$-0.31	$-0.26
High Forecast	$0.50	$0.41	$0.28	$0.17	$-0.03	$-0.09	$-0.11	$-0.11	$-0.10	$-0.29	$-0.25	$-0.17	$-0.21	$-0.27	$-0.32	$-0.36	$-0.33	$-0.37	$-0.31	$-0.36	$-0.34	$-0.42	$-0.34	$-0.35	$-0.28	$-0.31	$-0.26
Low Forecast	$0.37	$0.30	$0.21	$0.13	$-0.04	$-0.12	$-0.15	$-0.23	$-0.47	$-0.39	$-0.34	$-0.23	$-0.44	$-0.36	$-0.42	$-0.49	$-0.44	$-0.37	$-0.31	$-0.36	$-0.34	$-0.42	$-0.34	$-0.35	$-0.28	$-0.31	$-0.26
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.63%	-5.38%	-	4.03%	0.75%	1.70%	2.02%	1.97%	1.77%	1.55%	1.63%	7.62%

According to 3 Wall Street analysts, Legend Biotech's projected average Quarter EPS for Mar 23 is $-0.42, with a low estimate of $-0.49 and a high estimate of $-0.36. This represents a -120.77% decrease compared to LEGN previous annual EPS of $2.01 (Dec 22).

Legend Biotech Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PLRX	Pliant Therapeutics	$12.43	$39.71	219.47%	Buy
DAWN	Day One Biopharmaceuticals	$13.31	$38.80	191.51%	Buy
APLS	Apellis Pharmaceuticals	$26.27	$74.50	183.59%	Buy
ZLAB	Zai Lab	$27.06	$75.50	179.01%	Buy
ETNB	89bio	$7.93	$22.00	177.43%	Buy
STOK	Stoke Therapeutics	$12.03	$30.60	154.36%	Buy
TERN	Terns Pharmaceuticals	$6.17	$14.25	130.96%	Buy
LEGN	Legend Biotech	$38.19	$82.69	116.52%	Buy
AKRO	Akero Therapeutics	$28.09	$46.00	63.76%	Buy
ASND	Ascendis Pharma	$126.51	$190.21	50.35%	Buy
PCVX	Vaxcyte	$86.83	$124.00	42.81%	Buy
BPMC	Blueprint Medicines	$88.69	$109.71	23.70%	Buy
TVTX	Travere Therapeutics	$17.72	$21.75	22.74%	Buy
AMLX	Amylyx Pharmaceuticals	$4.76	$5.33	11.97%	Buy
MDGL	Madrigal Pharmaceuticals	$288.58	$315.75	9.42%	Buy
ALNY	Alnylam Pharmaceuticals	$235.56	$254.21	7.92%	Buy
ACLX	Arcellx	$87.83	$83.00	-5.50%	Buy
KRTX	Karuna Therapeutics	$329.83	$257.50	-21.93%	Buy

LEGN Forecast FAQ

Is Legend Biotech a good buy?

Yes, according to 14 Wall Street analysts, Legend Biotech (LEGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 13 'Buy' recommendations, accounting for 92.86% of LEGN's total ratings.

What is LEGN's price target?

Legend Biotech (LEGN) average price target is $82.69 with a range of $60 to $94, implying a 116.52% from its last price of $38.19. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Legend Biotech stock go up soon?

According to Wall Street analysts' prediction for LEGN stock, the company can go up by 116.52% (from the last price of $38.19 to the average price target of $82.69), up by 146.14% based on the highest stock price target, and up by 57.11% based on the lowest stock price target.

Can Legend Biotech stock reach $60?

LEGN's average twelve months analyst stock price target of $82.69 supports the claim that Legend Biotech can reach $60 in the near future.

What is Legend Biotech's current price target trend?

1 Wall Street analyst forecast a $83 price target for Legend Biotech (LEGN) this month, up 117.33% from its last price of $38.19. Compared to the last 3 and 12 months, the average price target increased by 134.62% and increased by 119.74%, respectively.

What are Legend Biotech's analysts' financial forecasts?

Legend Biotech's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.02B (high $1.15B, low $926.66M), average EBITDA is $-1.02B (high $-927M, low $-1.146B), average net income is $-82.359M (high $-62.314M, low $-98.233M), average SG&A $1.1B (high $1.23B, low $997.67M), and average EPS is $-0.451 (high $-0.341, low $-0.538). LEGN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.66B (high $1.88B, low $1.5B), average EBITDA is $-1.659B (high $-1.498B, low $-1.881B), average net income is $211.71M (high $248.56M, low $184.94M), average SG&A $1.79B (high $2.03B, low $1.61B), and average EPS is $1.16 (high $1.36, low $1.01).

Did the LEGN's actual financial results beat the analysts' financial forecasts?

Based on Legend Biotech's last annual report (Dec 2022), the company's revenue was $117M, which missed the average analysts forecast of $123.3M by -5.11%. Apple's EBITDA was $-437M, beating the average prediction of $-123M by 254.77%. The company's net income was $-446M, beating the average estimation of $-258M by 72.72%. Apple's SG&A was $174.05M, beating the average forecast of $131.45M by 32.41%. Lastly, the company's EPS was $-2.81, beating the average prediction of $-1.415 by 98.56%. In terms of the last quarterly report (Mar 2023), Legend Biotech's revenue was $36.34M, missing the average analysts' forecast of $42.18M by -13.85%. The company's EBITDA was $-127M, beating the average prediction of $-42.177M by 200.78%. Legend Biotech's net income was $-112M, beating the average estimation of $-76.227M by 47.06%. The company's SG&A was $40.16M, missing the average forecast of $45.41M by -11.56%. Lastly, the company's EPS was $-0.68, beating the average prediction of $-0.417 by 62.89%